HHS Grants Small Pharmacies Peptide Access
Tap title to read story
The Department of Health and Human Services will let small compounding pharmacies make six peptides that haven't been approved by the Food and Drug Administration.
HHS said in a new policy that it will exercise enforcement discretion for a half dozen peptides, essentially looking the other way when they're made by small compounding pharmacies.
Health Secretary Robert F.
Kennedy Jr. has been a vocal supporter of peptides, saying he has used some of them himself.
The peptides, and some of their unproven uses, are BPC‑157 for ulcerative colitis, Epitalon for insomnia, KPV for wound healing, MOTS‑c for metabolic health, Semax for migraine, and TB‑500 for wound healing.
More context
Timeline
- 2026-10-28 — HHS Grants Small Pharmacies Peptide Access
Why it matters
Immediate US impact: Immediate policy eases access for small pharmacies Possible long-term US impact: Long‑term supply may remain limited Most affected groups: Small compounding pharmacies and consumers Reader priority: Understand policy scope and supply limits
Coverage notes
Center: Coverage from houstonpublicmedia.org, wliw.org, politico.com frames this as a developing news story: HHS Grants Small Pharmacies Peptide Access. Reporting emphasizes verified facts, named sources, and near-term impact for readers. Left: Left-leaning desks covering the same development typically emphasize public impact, institutional accountability, and who is most affected. Right: Right-leaning desks covering the same development typically emphasize practical outcomes, market or security stakes, and institutional response.
Primary report
NPR — HHS Grants Small Pharmacies Peptide Access
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
